MSHLTrastuzumab Emtansine Powder For Concentrate For Solution For Infusion 100 mg, 160 mg
1) Adjuvant treatment of HER2 positive early breast cancer in patients with residual invasive disease, after neoadjuvant treatment with trastuzumab and a taxane. Maximum 14 cycles.
2) Treatment of HER2-positive, locally advanced, unresectable, or metastatic breast cancer in patients who have received prior treatment with trastuzumab and chemotherapy.